Patents by Inventor Luca Francesco
Luca Francesco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11267535Abstract: A mooring buoy includes a first floating body, a second body slidingly connected to the first and normally submerged, a mooring line connected to the second body by a connector housed in a seat in the first body and movable between a retracted position and a protruding position, enabling fixing the mooring line. The buoy further includes at least one chamber, in one or both of the first and second bodies, a fluid circuit admitting fluid into and out of the chamber, and a control unit connected to the fluid circuit. The control unit controls the fluid circuit to vary the amount of the fluid in the chamber, causing a variation of the immersion depth of the first body with respect to the second body or vice versa and, consequently, movement of the connecting element between the retracted and protruding positions.Type: GrantFiled: November 7, 2018Date of Patent: March 8, 2022Inventors: Bonfiglio Platè, Luca Francesco Maria Rovere, Paolo Saltarelli
-
Patent number: 11247743Abstract: A motorcycle includes an internal combustion engine, a frame, a fuel tank for carrying a fuel to be consumed by the internal combustion engine, and a container connected to the internal combustion engine and the fuel tank. The container is configured to store fuel evaporating from the fuel tank, and the container in a position of use is at least partially covered by the fuel tank. The fuel tank is supported pivotably relative to the frame between a maintenance position and the position of use.Type: GrantFiled: December 18, 2019Date of Patent: February 15, 2022Assignee: KTM AGInventors: Juan Domenech, Luca Francesco Contardo
-
Publication number: 20200317301Abstract: A mooring buoy includes a first floating body, a second body slidingly connected to the first and normally submerged, a mooring line connected to the second body by a connector housed in a seat in the first body and movable between a retracted position and a protruding position, enabling fixing the mooring line. The buoy further includes at least one chamber, in one or both of the first and second bodies, a fluid circuit admitting fluid into and out of the chamber, and a control unit connected to the fluid circuit. The control unit controls the fluid circuit to vary the amount of the fluid in the chamber, causing a variation of the immersion depth of the first body with respect to the second body or vice versa and, consequently, movement of the connecting element between the retracted and protruding positions.Type: ApplicationFiled: November 7, 2018Publication date: October 8, 2020Inventors: Bonfiglio PLATÈ, Luca Francesco Maria ROVERE, Paolo SALTARELLI
-
Publication number: 20200198717Abstract: A motor cycle includes an internal combustion engine, a frame, a fuel tank for carrying a fuel to be consumed by the internal combustion engine, and a container connected to the internal combustion engine and the fuel tank. The container is adapted to store fuel evaporating from the fuel tank, and the container in a position of use is at least partially covered by the fuel tank. The fuel tank is supported pivotably relative to the frame between a maintenance position and the position of use.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Inventors: Juan DOMENECH, Luca Francesco CONTARDO
-
Patent number: 9580416Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk) having the structure of Formula (B): Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: July 2, 2015Date of Patent: February 28, 2017Assignee: PHARMACYCLICS LLCInventors: Wei Chen, Longcheng Wang, Shunqi Yan, David J. Loury, Zhaozhong J. Jia, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Gordana Babic Atallah, Riccardo Zanaletti, Maria Pia Catalani, Luca Francesco Raveglia
-
Patent number: 9290450Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.Type: GrantFiled: April 28, 2014Date of Patent: March 22, 2016Assignee: InterMune, Inc.Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid D. Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
-
Publication number: 20160002225Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: July 2, 2015Publication date: January 7, 2016Inventors: Wei CHEN, Longcheng WANG, Shunqi YAN, David J. LOURY, Zhaozhong J. JIA, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Gordana Babic ATALLAH, Riccardo ZANALETTI, Maria Pia CATALANI, Luca Francesco RAVEGLIA
-
Patent number: 8969347Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.Type: GrantFiled: October 15, 2012Date of Patent: March 3, 2015Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
-
Publication number: 20140235637Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.Type: ApplicationFiled: April 28, 2014Publication date: August 21, 2014Applicant: InterMune, Inc.Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid D. Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
-
Patent number: 8304413Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.Type: GrantFiled: June 3, 2009Date of Patent: November 6, 2012Assignee: Intermune, Inc.Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
-
Patent number: 8063039Abstract: A method for treating pain, migraine, inflammation, gastrointestinal tract disorders, disorders of the genito-urinary tract, ophthalmic diseases or obesity in a subject, the method including administering to the subject an effective amount of a compound of a general formula, specific examples of which include 3-(4-Butyloxy-benzylamino)-pyrrolidin-2-one, 3-[4-(4-trifluorobutyloxy)-benzylamino]-pyrrolidin-2-one, 3-(4-Pentyloxy-benzylamino)-pyrrolidin-2-one, 3-[4-(5-trifluoropentyloxy)-benzylamino]-pyrrolidin-2-one, and 3-(4-Phenylethyl-benzylamino)-pyrrolidin-2-one.Type: GrantFiled: November 2, 2009Date of Patent: November 22, 2011Assignee: Newron Pharmaceuticals S.p.A.Inventors: Florian Thaler, Cibele Maria Sabido David, Sara Maestroni, Luca Francesco Raveglia, Patricia Salvati
-
Patent number: 7968592Abstract: 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases.Type: GrantFiled: November 16, 2004Date of Patent: June 28, 2011Assignee: Newron Pharmaceuticals S.p.A.Inventors: Florian Thaler, Cibele Maria Sabido David, Sara Maestroni, Luca Francesco Raveglia, Patricia Salvati
-
Publication number: 20100048665Abstract: 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases.Type: ApplicationFiled: November 2, 2009Publication date: February 25, 2010Applicant: NEWRON PHARMACEUTICALS S.p.A.,Inventors: Florian THALER, Cibele Maria Sabido David, Sara Maestroni, Luca Francesco Raveglia, Patricia Salvati
-
Patent number: 7482458Abstract: NK3 receptor antagonists of formula (I): are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.Type: GrantFiled: March 21, 2006Date of Patent: January 27, 2009Assignee: SmithKline Beecham Farmaceutica S.p.A.Inventors: Carlo Farina, Giuseppe Arnaldo Maria Giardina, Mario Grugni, Luca Francesco Raveglia
-
Patent number: 6780875Abstract: A compound, or a solvate or a salt thereof, of formula (I): wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted C5-7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is hydrogen, linear or branched C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl; R1 represents hydrogen or up to three optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-C1-6 alkylamino, R2 represents a moiety —(CH2)n—NYY2 wherein n is an integer in the range of from 1 to 9, Y1 and Y2 are independently selected from C1-6-alkyl; C1-6 alkyl substituted with hydroxy, alkoxy, C1-6 alkylamino or bis (C1-6 alkyl) amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C1-6-alkenyl; aryl or aryl-C1-6-alkyl or Y1 and Y2 together with the nitType: GrantFiled: February 5, 2003Date of Patent: August 24, 2004Assignees: SmithKline Beecham S.p.A., SmithKline Beecham Laboratories PharmaceutiquesInventors: Carlo Farina, Giuseppe Giardina, Mario Grugni, Marcel Morvan, Guy Marguerite Marie Gérard Nadler, Luca Francesco Raveglia
-
Publication number: 20040116469Abstract: A compound, or a solvate or a salt thereof, of formula (I): wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or a C5-7 cycloalkyl group or an optionally substituted single or fused ring aromatic heterocyclic group; R is C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or R is a group —(CH2)p— wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar, R1 represents hydrogen or up to four optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, hType: ApplicationFiled: November 25, 2003Publication date: June 17, 2004Applicant: SmithKline Beecham SpAInventors: Giuseppe Arnaldo Maria Giardina, Mario Grugni, Davide Graziani, Luca Francesco Raveglia
-
Patent number: 6743804Abstract: The present invention relates to a novel use, in particular a novel pharmaceutical use for a series of quinoline derivatives.Type: GrantFiled: May 7, 2002Date of Patent: June 1, 2004Assignee: SmithKline Beecham S p.A.Inventors: Giuseppe Arnaldo Maria Giardina, Carlo Farina, Mario Grugni, Luca Francesco Raveglia
-
Publication number: 20040067959Abstract: Compounds of formula (I) in which R1 is hydrogen or alkyl; R2 is hydrogen or one or more alkyl groups; R3 is R1 or R1X—; wherein R1 is hydrogen or optionally substituted alkyl, aryl, arylalkyl, cycloalkyl or heterocyclyl and X is a linking group; and R4 is hydrogen or alkyl; with the proviso that when R4 is methyl and R3 is methyl or hydroxyethyl then R2 is not hydrogen. Are selective delta opioid receptor ligands and therefore of potential therapeutic utility as analgesics and antihyperalgesics for different pain conditions; immunosuppressants to prevent rejection in organ transplant and skin grafts; anti-allergic and anti-inflammatory agents; brain cell protectants; agents for treating drug and alcohol abuse, gastritis, diarrhoea, cardiovascular and respiratory diseases, cough, mental illness and epilepsy.Type: ApplicationFiled: October 3, 2003Publication date: April 8, 2004Inventors: Giulio Dondio, Stefania Gagliardi, Davide Graziani, Luca Francesco
-
Patent number: 6696457Abstract: Heterocycle condensed morphinoid derivatives of formula (I) have therapeutic utility as analgesics, in collagen disease, as anti-allergic and anti-inflammatory agents, brain cell protectants, in gastritis, diarrhoea, cardiovascular and respiratory diseases, cough, mental illness, epilepsy, for the preservation of organs during transplant operations, and for the treatment of those pathological conditions which customarily can be treated with agonists of the delta opioid receptor.Type: GrantFiled: April 2, 2002Date of Patent: February 24, 2004Assignees: SmithKline Beecham p.l.c., SmithKline Beecham S.p.A.Inventors: Stephen Edward Clarke, Giulio Dondio, Luca Francesco Raveglia, Silvano Ronzoni
-
Patent number: RE47142Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.* Azuma et al., “A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan”, Am J Respir Crit Care Med., 165:A729 (2002). Badger, et al.Type: GrantFiled: November 6, 2014Date of Patent: November 27, 2018Assignee: InterMune, Inc.Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu